These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 22751085)

  • 21. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?
    Martinelli P; Contin M; Scaglione C; Riva R; Albani F; Baruzzi A
    Neurol Sci; 2003 Oct; 24(3):192-3. PubMed ID: 14598082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The L-dopa test in Parkinson's disease].
    Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y
    Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
    Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
    Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sex differences in the pharmacokinetics of levodopa in elderly patients with Parkinson disease.
    Kumagai T; Nagayama H; Ota T; Nishiyama Y; Mishina M; Ueda M
    Clin Neuropharmacol; 2014; 37(6):173-6. PubMed ID: 25384078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of ageing on the pharmacokinetics of levodopa in elderly patients with Parkinson's disease.
    Nagayama H; Ueda M; Kumagai T; Tsukamoto K; Nishiyama Y; Nishimura S; Hamamoto M; Katayama Y
    Parkinsonism Relat Disord; 2011 Mar; 17(3):150-2. PubMed ID: 21172738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
    Contin M; Martinelli P; Mochi M; Riva R; Albani F; Baruzzi A
    Mov Disord; 2005 Jun; 20(6):734-9. PubMed ID: 15747357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Central acute D2 stimulation worsens bladder function in patients with mild Parkinson's disease.
    Brusa L; Petta F; Pisani A; Miano R; Stanzione P; Moschella V; Galati S; Finazzi Agrò E
    J Urol; 2006 Jan; 175(1):202-6; discussion 206-7. PubMed ID: 16406911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
    Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA
    Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease.
    Arabia G; Zappia M; Bosco D; Crescibene L; Bagalà A; Bastone L; Caracciolo M; Scornaienghi M; Quattrone A
    Neurol Sci; 2002 Sep; 23 Suppl 2():S53-4. PubMed ID: 12548340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
    Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
    Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
    Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
    J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study.
    Kulisevsky J; Pascual-Sedano B; Barbanoj M; Gironell A; Pagonabarraga J; García-Sánchez C
    Mov Disord; 2007 Jan; 22(1):62-7. PubMed ID: 17115388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of levodopa on reduced nerve growth factor levels in patients with Parkinson disease.
    Müller T; Lang UE; Muhlack S; Welnic J; Hellweg R
    Clin Neuropharmacol; 2005; 28(5):238-40. PubMed ID: 16239764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects.
    Gasser UE; Crevoisier C; Ouwerkerk M; Lankhaar G; Dingemanse J
    Eur J Pharm Biopharm; 1998 Sep; 46(2):223-8. PubMed ID: 9795070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and dose proportionality of domperidone in healthy volunteers.
    Huang YC; Colaizzi JL; Bierman RH; Woestenborghs R; Heykants JJ
    J Clin Pharmacol; 1986; 26(8):628-32. PubMed ID: 3793955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of silymarin pretreatment on the bioavailability of domperidone in healthy human volunteers.
    Yamsani SK; Yamsani MR
    Drug Metabol Drug Interact; 2014; 29(4):261-7. PubMed ID: 25029082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease. Effect on levodopa bioavailability.
    Contin M; Riva R; Martinelli P; Procaccianti G; Albani F; Baruzzi A
    Clin Neuropharmacol; 1991 Apr; 14(2):148-55. PubMed ID: 2015611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid intravenous loading of levodopa for human research: clinical results.
    Black KJ; Carl JL; Hartlein JM; Warren SL; Hershey T; Perlmutter JS
    J Neurosci Methods; 2003 Jul; 127(1):19-29. PubMed ID: 12865145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.